The Motley Fool
12 Jun 2026, 05:15 UTC · 3h ago
Is Viking Therapeutics Stock Going to $100?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
The Motley Fool
12 Jun 2026, 05:15 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Viking Therapeutics expects to report data from a maintenance dosing study of its weight loss drug candidate in the third quarter. — Clinical data readouts for weight loss candidates are primary volatility drivers for biotech stocks.
+0.60Viking aims to launch a phase 3 trial for the oral version of its candidate VK2735 in the fourth quarter. — Advancing to phase 3 is a critical milestone that reduces regulatory risk and brings the company closer to commercialization.
+0.50VK2735 is being developed as a dual GLP-1/GIP receptor agonist in both injectable and oral formats. — Offering both formulations creates a competitive differentiation and a flexible treatment path for patients compared to current market leaders.
+0.40Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The article highlights a promising drug candidate in late-stage trials and potential for blockbuster revenue in a high-growth market.
Mentioned as a market leader with blockbuster drugs and high demand, though facing potential new competition.
Mentioned as a market leader with blockbuster drugs and high demand, though facing potential new competition.
[mutual] Eli Lilly and Novo Nordisk are described as pharma giants and market leaders dominating the weight loss drug space.
[mutual] Viking Therapeutics is developing a weight loss drug candidate to compete with Eli Lilly's market-leading products.
[mutual] Viking Therapeutics is developing a weight loss drug candidate to compete with Novo Nordisk's market-leading products.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
8h ago
